Compare · KRYS vs LEGN
KRYS vs LEGN
Side-by-side comparison of Krystal Biotech Inc. (KRYS) and Legend Biotech Corporation (LEGN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. KRYS focuses on Biotechnology: Biological Products (No Diagnostic Substances), while LEGN focuses on Biotechnology: Pharmaceutical Preparations.
- KRYS is the larger of the two at $9.13B, about 1.5x LEGN ($6.19B).
- Over the past year, KRYS is up 123.8% and LEGN is down 11.0% - KRYS leads by 134.7 points.
- KRYS has been more active in the news (7 items in the past 4 weeks vs 5 for LEGN).
- LEGN has more recent analyst coverage (25 ratings vs 17 for KRYS).
- Company
- Krystal Biotech Inc.
- Legend Biotech Corporation
- Price
- $309.62+2.56%
- $33.50+6.33%
- Market cap
- $9.13B
- $6.19B
- 1M return
- +1.27%
- +19.17%
- 1Y return
- +123.76%
- -10.98%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2020
- News (4w)
- 7
- 5
- Recent ratings
- 17
- 25
Krystal Biotech Inc.
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and acne scars; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx for other rare lung disease. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
Legend Biotech Corporation
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in North America and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in relapsed and refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates targeting various cancers, including non-hodgkins lymphoma (NHL), acute myeloid leukemia, and T cell lymphoma. In addition, it is developing allogeneic CAR-T product candidates targeting CD20 for the treatment of NHL and targeting B-cell maturation antigen for the treatment of MM, which are currently in an investigator-initiated Phase 1 clinical trial in China. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
Latest KRYS
- President, R&D Krishnan Suma sold $7,702,825 worth of shares (25,000 units at $308.11) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 1,378,155 units (SEC Form 4)
- President and CEO Krishnan Krish S sold $7,702,984 worth of shares (25,000 units at $308.12) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 1,450,253 units (SEC Form 4)
- SEC Form 144 filed by Krystal Biotech Inc.
- SEC Form 144 filed by Krystal Biotech Inc.
- EVP, General Counsel Thomas John Charles sold $193,903 worth of shares (642 units at $302.03) as part of a pre-agreed trading plan, closing all direct ownership in the company (SEC Form 4)
- Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call
- Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
- Krystal Biotech to Present at BofA Securities 2026 Health Care Conference
- Amendment: SEC Form SCHEDULE 13G/A filed by Krystal Biotech Inc.
- Krystal Biotech Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest LEGN
- SEC Form 6-K filed by Legend Biotech Corporation
- Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)
- SEC Form 6-K filed by Legend Biotech Corporation
- Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026
- SEC Form 6-K filed by Legend Biotech Corporation
- SEC Form 6-K filed by Legend Biotech Corporation
- Legend Biotech Reports First Quarter 2026 Results and Recent Highlights
- Legend Biotech Expands Scientific Advisory Expertise to Inform Future Growth
- Legend Biotech to Host Investor Conference Call on First Quarter 2026 Results
- SEC Form 6-K filed by Legend Biotech Corporation